Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls - Summary - MDSpire
Advertisement
Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls
To explore the hospital and pharmaceutical resource use and costs associated with cardiovascular disease in patients with genetically verified familial hypercholesterolaemia (FH) from 2010 to 2019 compared to age- and sex-matched controls.
Key Findings:
FH patients had CVD-related costs of €3911 for hospital care and €6119 for pharmaceuticals, compared to €1498 and €514 for controls.
Costs for percutaneous coronary interventions were €561 for FH and €140 for controls.
Pharmaceutical costs for FH patients doubled during the study period, largely due to new drug introductions.
Interpretation:
Patients with familial hypercholesterolaemia incur significantly higher costs related to cardiovascular disease compared to matched controls, highlighting the need for targeted healthcare strategies.
Limitations:
The study is limited to data from Norway, which may not be generalizable to other healthcare systems.
Potential biases in registry data and patient selection may affect the findings, potentially leading to an underestimation or overestimation of costs.
Conclusion:
Familial hypercholesterolaemia patients face substantially higher cardiovascular-related healthcare costs, emphasizing the need for targeted healthcare strategies and resource allocation to address these disparities.
